Blanket Purchase Agreement 36F79720D0153-36E79722A0022
Award Date
6/17/22
Last Date to Order
6/16/26
Federal Agency
National Acquisition Center
Awardee
Xeris Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) awarded Xeris Pharmaceuticals, Inc., a small disadvantaged business manufacturer, a multiple-award Federal Supply Schedule (FSS) contract under FSS-61-IB for Pharmaceuticals and Drugs. The $4,119,200 contract has a period of performance from July 2020 to July 2025, allowing the VA's Integrated Service Network 12 to procure a range of Xeris' drug therapies, pharmaceuticals, and hematology products to support healthcare operations for veteran patients....
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Eiger Biopharmaceuticals, Inc. for an estimated potential value of $205,000. No set-aside was used. The BPA is for the drug Zokinvy to treat progeroid laminopathies, a group of rare premature aging diseases. Eiger Biopharmaceuticals will supply Zokinvy to the VA through May 13, 2022 under the terms of this agreement. As the federal agency responsible for healthcare and benefits for...
The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, which is a civilian agency under the Department of Veterans Affairs (VA), to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business. The BPA has a ceiling value of $1,406.70 and a period of performance through March 2026. The purpose of this BPA is to facilitate the procurement of the pharmaceutical product KYZATREX by VA medical centers nationwide. Marius Pharmaceuticals, which holds a...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Akebia Therapeutics, Inc. as a single-award contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA has a ceiling value of $10,254,764.65 and a period of performance from April 25, 2025 to April 24, 2026. The purpose of this BPA is to provide the VA with the pharmaceutical products VAFSEO and AURYXIA. No set-asides were used for this award....
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business organized as a limited liability company. The BPA has a ceiling value of $10,000,000 and a period of performance through January 31, 2024. The primary purpose of this BPA is to facilitate the procurement of a specific pharmaceutical product called KYZATREX by the Department of Veterans Affairs (VA) and its...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA) to Vifor (International) AG, a Swiss-based pharmaceutical manufacturer, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $150,000 BPA, which expires on June 24, 2026, is specifically for the procurement of KORSUVA (difelikefalin), a medication used to treat pruritus. Additionally, Vifor (International) AG holds a separate $23.8 million...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Catalyst Pharmaceuticals, Inc. The BPA, valued at $5,500,000, is placed against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of July 25, 2026. The primary purpose of this BPA is to enable the procurement of the pharmaceutical product Firdapse (amifampridine), an FDA-approved...